-
11.发明授权Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV 有权通过施用二肽基肽酶IV抑制剂提高低血糖哺乳动物血糖水平公开(公告)号：US06319893B1
公开(公告)日：2001-11-20
申请号：US09365404
申请日：1999-08-02
IPC分类号： A01N3718
CPC分类号： A61K38/26
摘要： A method of raising the blood sugar level in a mammal having hypoglycemia is described. The method reduces degradation of glucagon by administering to the mammal a therapeutically effective amount of an inhibitor of dipeptidyl peptidase IV and physiologically acceptable adjuvants and/or excipients.
摘要翻译： 描述了一种提高低血糖哺乳动物血糖水平的方法。 该方法通过向哺乳动物施用治疗有效量的二肽基肽酶IV抑制剂和生理上可接受的佐剂和/或赋形剂来降低胰高血糖素的降解。
-
公开(公告)号：US08470781B2
公开(公告)日：2013-06-25
申请号：US12182113
申请日：2008-07-29
申请人： Stephan Schilling , Torsten Hoffmann , Andre Johannes Niestroj , Hans-Ulrich Demuth , Ulrich Heiser
发明人： Stephan Schilling , Torsten Hoffmann , Andre Johannes Niestroj , Hans-Ulrich Demuth , Ulrich Heiser
IPC分类号： C07K5/06
CPC分类号： A61K31/00 , A61K31/13 , A61K31/416 , A61K31/4178 , A61K31/4184 , A61K38/06 , A61K38/07 , A61K38/08
摘要： The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o Heliobacter pylori infections, colorectal cancer, Zolliger-Ellison syndrome, Familial British Dementia and Familial Danish Dementia.
摘要翻译： 本发明提供哺乳动物谷氨酰胺酰环化酶（QC，EC 2.3.2.5）的新生理底物，QC的新效应物以及包含这些效应物的这些效应物和药物组合物的用途，用于治疗可通过调节QC- 活动，例如 选自由具有或不具有幽门螺旋杆菌感染的十二指肠癌，结肠直肠癌，佐立格 - 埃利森综合征，家族性英国痴呆和家族性丹麦痴呆组成的组的疾病。
-
公开(公告)号：US20130052203A1
公开(公告)日：2013-02-28
申请号：US13571947
申请日：2012-08-10
申请人： Sigrid Graubner , Wolfgang Jagla , Stephan Schilling , Holger Cynis , Hans-Ulrich Demuth , Torsten Hoffmann , Michael Wermann , Katrin Schulz , Christoph Baeuscher , Stefanie Kohlmann
发明人： Sigrid Graubner , Wolfgang Jagla , Stephan Schilling , Holger Cynis , Hans-Ulrich Demuth , Torsten Hoffmann , Michael Wermann , Katrin Schulz , Christoph Baeuscher , Stefanie Kohlmann
IPC分类号： A01K67/027 , A61K49/00 , C12N5/071 , C07K16/40 , A61K39/395 , A61P11/00 , A61P25/18 , A61P35/00 , A61P19/02 , A61P35/04 , A61P9/10 , A61P1/18 , A01K67/02 , A61P25/28
CPC分类号： A01K67/0278 , A01K2217/052 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0312 , C07K14/4711 , C12N9/104
摘要： A double transgenic non-human animal, in particular a transgenic mouse encoding Qpct proteins, which have been implicated in Qpct-related diseases, and Amyloid Precursor Protein (APP). Also provided are cells and cell lines comprising transgenes encoding for Qpct and APP. Also provided are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
摘要翻译： 双重转基因非人动物，特别是编码Qpct蛋白的转基因小鼠，其涉及Qpct相关疾病，和淀粉样前体蛋白（APP）。 还提供了包含编码Qpct和APP的转基因的细胞和细胞系。 还提供了用于评估影响Qpct的药剂的方法和组合物，用于治疗Qpct相关疾病的组合物。
-
公开(公告)号：US20090183267A1
公开(公告)日：2009-07-16
申请号：US12353463
申请日：2009-01-14
IPC分类号： G01N33/48 , A01K67/027 , C12Q1/68 , C12N5/10 , A61K38/16
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C12N9/104 , C12N15/8509 , C12N2800/30 , G01N2500/00 , G01N2800/2814
摘要： The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
摘要翻译： 本发明提供了敲除非人动物，特别是携带Qpct敲除突变的小鼠。 本发明另外提供了用于评价影响Qpct的药剂的各种细胞和细胞系以及用于评估用于治疗Qpct相关疾病的组合物的方法和组合物。
-
15.发明申请Use of Inhibtors of Glutaminyl Cyclases for Treatment and Prevention of Disease 有权谷氨酰胺酰化酶抑制剂用于治疗和预防疾病的应用公开(公告)号：US20080286810A1
公开(公告)日：2008-11-20
申请号：US12101497
申请日：2008-04-11
申请人： Hans-Ulrich Demuth , Torsten Hoffmann , Andre Johannes Niestroj , Stephan Schilling , Ulrich Heiser
发明人： Hans-Ulrich Demuth , Torsten Hoffmann , Andre Johannes Niestroj , Stephan Schilling , Ulrich Heiser
CPC分类号： C07F9/6561 , A61K31/00 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , C07D231/12 , C07D233/54 , C07D403/06 , C07D405/06 , C07D409/06 , C07D471/04 , C07F9/572 , C07F9/59 , C07F9/6506
摘要： Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.
摘要翻译： 哺乳动物谷氨酰胺酰环化酶（QC，EC 2.3.2.5）的新型生理底物，QC的新效应物，筛选此类效应物的方法，以及包含这些效应物的这种效应物和药物组合物的用途，用于治疗可由 调节QC活性。 优选的组合物另外包含用于治疗或减轻可以通过调节QC和DP IV-活性治疗的病症的DP IV或DP IV样酶的抑制剂。
-
公开(公告)号：US20060293248A1
公开(公告)日：2006-12-28
申请号：US11481349
申请日：2006-07-05
IPC分类号： A61K38/04 , A61K31/426 , A61K31/401
CPC分类号： A61K31/401 , A61K31/426 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/55
摘要： The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.
-
公开(公告)号：US07084120B2
公开(公告)日：2006-08-01
申请号：US09745776
申请日：2000-12-22
CPC分类号： C07K5/06165 , A61K38/00 , C07K5/06173 , C07K5/0806 , C07K5/0808 , C07K5/0823
摘要： Prodrug compounds of unstable inhibitors of the serine peptidase dipeptidyl peptidase IV, are used in the treatment of various disorders, especially of metabolic disorders. The Prodrug compounds can be used in the treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy.
摘要翻译： 丝氨酸肽酶二肽基肽酶IV的不稳定抑制剂的前药化合物用于治疗各种疾病，特别是代谢紊乱。 前药化合物可用于治疗葡萄糖耐量异常，糖尿病，高脂血症，代谢性酸痛，糖尿病，糖尿病性神经病变和肾病。
-
公开(公告)号：US06949515B2
公开(公告)日：2005-09-27
申请号：US10082001
申请日：2002-02-22
IPC分类号： A61K9/06 , A61K8/49 , A61K8/72 , A61K9/08 , A61K9/107 , A61K9/12 , A61K9/70 , A61K9/72 , A61K31/765 , A61K38/00 , A61K47/48 , A61P1/02 , A61P3/00 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07K5/037 , C07K5/06 , C07K5/072 , C07K5/083 , C07K5/113 , C07K7/06 , C07K7/08 , C08G65/329 , A61K31/33
CPC分类号： C07K5/06078 , A61K38/00 , C07K5/06104 , C07K5/0806 , C07K7/08 , C08G65/329
摘要： The invention relates to compounds for topically influencing the activity of dipeptidyl peptidase of the general formula wherein A is an amino acid having at least one functional group in the side chain; B is a chemical compound covalently bound to a functional group of the side chain of A, chosen from the group consisting of (a) oligopeptides having a chain length of up to 20 amino acids, (b) homopolymers of glycine consisting of up to 6 glycine monomers, and (c) polyethylene glycols having molar masses of up to 20 000 g/mol; and C is a group amide-bonded to A chosen from the group consisting of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine. The invention further relates to the use of said compounds for targeted intervention in local immunological processes (chemotaxis, inflammatory processes, autoimmune diseases), as well as effective and targeted treatment of pathophysiological and physiological processes related thereto (psoriasis, periodontitis, arthritis, allergies, inflammation), inter alia.
-
公开(公告)号：US09462793B2
公开(公告)日：2016-10-11
申请号：US12353463
申请日：2009-01-14
IPC分类号： C12N15/01 , A01K67/027 , C12N9/10 , C12N15/85
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C12N9/104 , C12N15/8509 , C12N2800/30 , G01N2500/00 , G01N2800/2814
摘要： The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
摘要翻译： 本发明提供了敲除非人动物，特别是携带Qpct敲除突变的小鼠。 本发明另外提供了用于评价影响Qpct的药剂的各种细胞和细胞系以及用于评估用于治疗Qpct相关疾病的组合物的方法和组合物。
-
公开(公告)号：US09181233B2
公开(公告)日：2015-11-10
申请号：US13040159
申请日：2011-03-03
IPC分类号： C07D235/04 , A61K31/4184 , C07D417/04 , C07D403/04 , C07D413/04
CPC分类号： C07D417/04 , A61K31/4184 , C07D235/04 , C07D403/04 , C07D413/04
摘要： The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
摘要翻译： 本发明涉及作为谷氨酰胺酰环化酶抑制剂的新型杂环衍生物（QC，EC 2.3.2.5）。 QC在氨释放下催化N-末端谷氨酰胺残基在焦谷氨酸（5-氧代 - 脯氨酰基，pGlu *）中的分子内环化，并且在释放水下将N-末端谷氨酸残基分子内环化成焦谷氨酸。
-
-
-
-
-
-
-
-
-
搜索结果
99 条记录 (耗时 0.046 秒)
